<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160402</url>
  </required_header>
  <id_info>
    <org_study_id>IGM-6268-001</org_study_id>
    <nct_id>NCT05160402</nct_id>
  </id_info>
  <brief_title>Evaluation of IGM-6268 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IGM Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IGM Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single (SAD)&#xD;
      and multiple ascending (MAD) ascending dose study to assess the safety, tolerability, and&#xD;
      pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy&#xD;
      volunteers. IGM-6268 or placebo will be administered by intranasal + intraoral spray using a&#xD;
      Teleflex Mucosal Atomization Device Nasal™ Intranasal Mucosal Atomization Device once (SAD),&#xD;
      or once or twice each day for 5 days (MAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IGM-6268 is an engineered Immunoglobulin M (IgM) antibody that specifically targets the&#xD;
      receptor binding domain (RBD) of the SARS-CoV-2 spike protein. This humanized pentameric IgM&#xD;
      antibody has 10 binding sites to the spike protein and a J-chain to enable the formation of&#xD;
      IgM pentamers.&#xD;
&#xD;
      IGM-6268 is being developed as a treatment for or prophylaxis of symptoms associated with&#xD;
      mild to moderate COVID-19. The primary mechanism of action of IGM-6268 is to block the&#xD;
      binding of the SARS-CoV-2 RBD on the spike protein to human angiotensin converting enzyme 2&#xD;
      (hACE2), the cellular receptor for SARS-CoV-2. By blocking this binding, IGM 6268 neutralizes&#xD;
      the infectivity of the virus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive intranasal and intraoral administration of IGM-6268 or placebo at the assigned doses. Cohorts will be enrolled sequentially.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Cohorts 1-6 will receive IGM-6268 or placebo. Subjects and Investigators will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; tolerability of IGM-6268 by assessing the number, severity, and type of adverse events per CTCAE 5.0</measure>
    <time_frame>Through 60 days following receipt of final dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGM-6268 in serum</measure>
    <time_frame>Predose through Day 3 (SAD) or Day 6 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-IGM-6268 antibodies in serum</measure>
    <time_frame>Prior to dosing and at Day 28 following receipt of initial dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 1, subjects will be randomized to receive a single intranasal and intraoral administration of 1 mg of IGM 6268 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 2, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 3, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 4, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo once a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 5, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 6, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice a day for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGM-6268</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Cohort 1 (SAD)</arm_group_label>
    <arm_group_label>Cohort 2 (SAD)</arm_group_label>
    <arm_group_label>Cohort 3 (SAD)</arm_group_label>
    <arm_group_label>Cohort 4 (MAD)</arm_group_label>
    <arm_group_label>Cohort 5 (MAD)</arm_group_label>
    <arm_group_label>Cohort 6 (MAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Cohort 1 (SAD)</arm_group_label>
    <arm_group_label>Cohort 2 (SAD)</arm_group_label>
    <arm_group_label>Cohort 3 (SAD)</arm_group_label>
    <arm_group_label>Cohort 4 (MAD)</arm_group_label>
    <arm_group_label>Cohort 5 (MAD)</arm_group_label>
    <arm_group_label>Cohort 6 (MAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age&#xD;
&#xD;
          -  Has a body mass index (BMI) &lt; 35 kg/m2.&#xD;
&#xD;
          -  Is healthy as determined by medical history, physical examination, 12-lead&#xD;
             electrocardiogram, laboratory assessments, and vital signs at screening.&#xD;
&#xD;
          -  For women of childbearing potential or men, agreement to use at least one highly&#xD;
             effective form of non-hormonal contraception or one highly effective form and one&#xD;
             effective form of non-hormonal contraception through the course of study treatment and&#xD;
             for 3 months after the last dose of IGM-6268.&#xD;
&#xD;
          -  Agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any COVID-19 vaccine or contemplating receipt of any COVID-19 vaccine (or&#xD;
             participating in a COVID-19 vaccine trial) during this study and follow-up periods&#xD;
             (approximately 65 days from enrollment). Subjects are permitted to withdraw at any&#xD;
             time if they decide to receive the vaccine&#xD;
&#xD;
          -  History of prior positive SARS-CoV-2 diagnostic test (antigen or NAAT), or positive&#xD;
             SARS-CoV-2 serology test, at any time before enrollment.&#xD;
&#xD;
          -  Confirmed or suspected pulmonary or systemic bacterial infection.&#xD;
&#xD;
          -  Current or planned participation in any interventional clinical trial during the study&#xD;
             and follow-up periods.&#xD;
&#xD;
          -  History of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.&#xD;
&#xD;
          -  Uncontrolled human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Nasal polyps (history or physical exam) or any structural abnormality of nose that, in&#xD;
             the opinion of the investigator, could compromise administration or receipt of study&#xD;
             drug (e.g., nasal septal deviation).&#xD;
&#xD;
          -  History of reactive airway disease or hypersensitivity to any component of study drug&#xD;
             or placebo.&#xD;
&#xD;
          -  Use of any nasally-administered drug between 5 days prior to study enrollment and 2&#xD;
             days after receipt of last dose administered.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roel Funke</last_name>
    <role>Study Director</role>
    <affiliation>IGM Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris Sison</last_name>
    <phone>510-329-9857</phone>
    <email>clinicaltrials@igmbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Caruano</last_name>
    <phone>408-838-2308</phone>
    <email>clinicaltrials@igmbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Arora, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

